Did you miss a session from the Future of Work Summit? Head over to our Future of Work Summit on-demand library to stream.
Tryton Medical, a developer of stent systems, announced today that it has raised $20 million in a fourth round of funding. The round was led by Arnerich Massena, with participation from PTV Sciences, RiverVest Partners and Spray Venture Partners. The company makes stents to treat bifurcated lesions, which are found where one artery branches off from another, and Tryton expects that these stents may come to replace coronary bypass surgery for treatment of coronary artery disease.
Based in Durham, North Carolina, the company announced yesterday that its stent system has expanded to new European countries, making it available in a total of 21 European and Middle Eastern countries. The product is not yet approved in the United States.
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more